drug_type
RELEVANT_DRUG
intervention_type
Experimental drug
drug_description
Autologous, gene-modified CD22-directed CAR T-cell therapy; engineered T cells activate upon CD22 engagement to proliferate and kill CD22+ B-cell lymphoma cells; may cause B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Drugs, Investigational
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD22-directed chimeric antigen receptor. Upon binding CD22 on B-cell lymphoma cells, CAR signaling (CD3zeta plus costimulatory domains) activates the T cells, driving proliferation, cytokine release, and perforin/granzyme-mediated killing of CD22+ cells, often causing on-target B-cell aplasia.
drug_name
firicabtagene autoleucel (firi-cel/CRG-022)
nct_id_drug_ref
NCT05972720